Analyst Ratings For Aerie Pharmaceuticals (NASDAQ:AERI)
Today, Canaccord Genuity reiterated its Buy rating on Aerie Pharmaceuticals (NASDAQ:AERI) with a price target of $86.00.
Some recent analyst ratings include
- 1/25/2018-Canaccord Genuity Reiterated Rating of Buy.
- 12/19/2017-Mizuho Reiterated Rating of Buy.
- 10/23/2017-Guggenheim initiated coverage with a Buy rating.
- 10/16/2017-Needham & Company LLC Reiterated Rating of Buy .
- 10/5/2017-Cowen Reiterated Rating of Buy.
- On 5/26/2017 Foresite Capital Fund Ii, L.P., Major Shareholder, sold 20,000 with an average share price of $55.95 per share and the total transaction amounting to $1,119,000.00.
- On 4/19/2017 Gerald D Cagle, Director, bought 2,000 with an average share price of $41.70 per share and the total transaction amounting to $83,400.00.
- On 2/15/2017 Geoffrey M Duyk, Director, sold 41,591 with an average share price of $46.63 per share and the total transaction amounting to $1,939,388.33.
- On 10/6/2016 Foresite Capital Fund Ii, L.P., Major Shareholder, sold 50,000 with an average share price of $40.34 per share and the total transaction amounting to $2,017,000.00.
- On 7/22/2016 Foresite Capital Fund Ii, L.P., Major Shareholder, bought 250,000 with an average share price of $17.50 per share and the total transaction amounting to $4,375,000.00.
- On 4/15/2015 Anand Mehra, Director, sold 425,000 with an average share price of $33.64 per share and the total transaction amounting to $14,297,000.00.
- On 1/8/2015 Lifesciences Ii L.P. Clarus, Major Shareholder, sold 175,000 with an average share price of $31.11 per share and the total transaction amounting to $5,444,250.00.
Recent Trading Activity for Aerie Pharmaceuticals (NASDAQ:AERI)
Shares of Aerie Pharmaceuticals closed the previous trading session at 57.25 up +1.75 3.15% with 112817 shares trading hands.